International Journal of Scientific Research in Engineering and Management (IJSREM)
Volume: 09 Issue: 05 | May - 2025 SJIF Rating: 8.586 ISSN: 2582-3930

Automated Prediction of Liver Disease Using Machine Learning: Enhancing Early Diagnosis and Clinical Decision-Making

P.Sreni

Dept. of CSE - AIML, Sreenidhi Institute of Science and technology

srenipulluri@gmail.com

M.Sripriya Bhargavi

Dept. of CSE - AIML, Sreenidhi Institute of Science and technology

sripriya9113@gmail.com

Reshma Shaik

Dept. of CSE - AIML, Sreenidhi Institute of Science and technology

reshmaashaik28@gmail.com

Dr.K.Shirisha

Head of the Department,

Dept. of CSE - AIML, Sreenidhi Institute of Science and technology

shirisha.k@sreenidhi.edu.in

Abstract . Liver disease remains a major global health concern, frequently resulting in severe complications and high mortality rates. Early and accurate diagnosis is essential for improving patient outcomes and mitigating the burden of liver-related conditions. This research proposes the development of an automated liver disease prediction system leveraging advanced machine learning algorithms to analyze user health data. The system is designed to assess clinical parameters and predict the likelihood of liver disease, providing valuable decision support to healthcare practitioners. A user-centric interface ensures ease of access and usability for both clinicians and individuals seeking preliminary assessments. By integrating predictive analytics, the proposed model facilitates the early identification of liver abnormalities, thereby enabling timely medical intervention. This approach not only enhances diagnostic accuracy but also contributes to more efficient healthcare delivery. The study underscores the transformative potential of machine learning in medical diagnostics, offering a scalable and reliable solution for liver disease management. Through automation and intelligent analysis, the system aims to support rapid, informed, and precise clinical decisions, ultimately improving patient care and health outcomes.

Keywords:
Liver Disease Prediction, Machine Learning, Early Diagnosis, Predictive Analytics, Clinical Decision Support

1 Introduction

1.1 Background on Liver Disease

Liver disease encompasses a broad spectrum of conditions affecting the liver, ranging from hepatitis and fatty liver to cirrhosis and liver cancer. These disorders often progress silently until advanced stages, making early detection critical for effective treatment. According to the World Health Organization, liver disease accounts for over two million deaths globally each year, highlighting its significant impact on public health [1]. Risk factors include alcohol consumption, viral infections (e.g., hepatitis B and C), obesity, and genetic predispositions [2]. Despite advances in medical treatment, the morbidity and mortality associated with liver conditions remain high, primarily due to delayed diagnosis and intervention.

1.2 Need for Early Diagnosis

Timely identification of liver abnormalities can dramatically improve prognosis by enabling early intervention and management strategies. Traditional diagnostic methods, such as liver function tests, imaging, and biopsies, are often invasive, time-consuming, and inaccessible in resource-limited settings [3]. Moreover, the subjective interpretation of clinical indicators may lead to inconsistent results. Hence, there is an urgent need for accurate, non-invasive, and efficient diagnostic tools that can support healthcare providers in detecting liver disease at an early stage [4].

1.3 Role of Technology in Healthcare

The integration of advanced technologies, particularly artificial intelligence (AI) and machine learning (ML), has opened new avenues in the healthcare domain. These technologies are capable of analyzing large volumes of medical data to uncover patterns and predict health outcomes with high precision [5]. Machine learning models have demonstrated substantial potential in clinical diagnostics by automating risk assessment and improving decision-making processes [6]. Specifically, in the context of liver disease, ML-driven systems can evaluate diverse patient parameters to generate reliable predictions, thereby facilitating early diagnosis and treatment planning. Such innovations not only enhance diagnostic accuracy but also contribute to cost-effective and scalable healthcare solutions [7].

2 Literature Review

2.1 Existing Diagnostic Methods

The diagnosis of liver diseases traditionally relies on a combination of clinical evaluations, laboratory tests, imaging modalities, and histopathological assessments. Liver function tests (LFTs) measure enzymes and proteins in the blood to assess liver health, while imaging techniques like ultrasound, computed tomography (CT), and magnetic resonance imaging (MRI) provide structural information. However, these methods may lack sensitivity in detecting early-stage liver fibrosis or steatosis. Liver biopsy remains the gold standard for definitive diagnosis, offering detailed histological insights. Nonetheless, biopsies are invasive, carry risks such as bleeding and infection, and may suffer from sampling errors due to the heterogeneous nature of liver pathology [8].
To address these limitations, non-invasive diagnostic tools have been developed. Transient elastography (TE), commercially known as FibroScan, measures liver stiffness to assess fibrosis. Similarly, shear wave elastography (SWE) utilizes ultrasound to evaluate tissue elasticity, aiding in the detection of liver fibrosis with greater reproducibility and less operator dependency [9]. Blood-based biomarkers, such as the Enhanced Liver Fibrosis (ELF) test, combine multiple serum markers to estimate fibrosis severity, offering a less invasive alternative to biopsy [10].

2.2 2.2 Recent Advances in Machine Learning in Healthcare

The integration of machine learning (ML) into healthcare has revolutionized diagnostic and prognostic processes. In hepatology, ML algorithms have been employed to predict the presence and progression of liver diseases using diverse datasets. For instance, ML models have been trained on routine clinical and laboratory data to identify non-alcoholic fatty liver disease (NAFLD) with high accuracy, facilitating early intervention [11]. Advanced algorithms, including support vector machines (SVMs), random forests, and neural networks, have demonstrated efficacy in distinguishing between different liver conditions, such as differentiating alcoholic liver disease from NAFLD, based on biochemical and imaging parameters [12].
Furthermore, ML has been applied to imaging data for the assessment of liver disease severity. Convolutional neural networks (CNNs) have shown promise in evaluating CT and MRI scans to stage liver fibrosis and cirrhosis, offering a non-invasive and automated approach to disease assessment [13]. These advancements not only enhance diagnostic accuracy but also reduce the burden on healthcare professionals by automating complex analyses.

2.3 Gaps in Current Liver Disease Prediction Systems

Despite the progress in ML applications for liver disease, several challenges persist. One significant issue is the lack of standardized and comprehensive datasets, which hampers the generalizability of ML models across diverse populations. Many studies rely on retrospective data from single centers, limiting the external validity of the findings [14]. Additionally, the "black box" nature of some ML algorithms raises concerns about interpretability and trust among clinicians, potentially hindering clinical adoption [15].Moreover, regulatory approval for ML-based diagnostic tools remains limited. While some AI applications have received clearance for clinical use, such as the AIM-NASH tool for assessing steatohepatitis severity, widespread implementation is constrained by regulatory, ethical, and infrastructural barriers [16]. Addressing these gaps requires collaborative efforts to develop robust, transparent, and clinically validated ML models that can be seamlessly integrated into healthcare systems.

3 Methodology

3.1 Data Collection and Preprocessing

The dataset used for this study is the Indian Liver Patient Dataset (ILPD), obtained from the UCI Machine Learning Repository. It contains 583 records and 10 medical attributes, including:

- Age
- Gender
- Total Bilirubin
- Direct Bilirubin
- Alkaline Phosphotase

- Alamine Aminotransferase (SGPT)
- Aspartate Aminotransferase (SGOT)
- Total Proteins
- Albumin
- Albumin and Globulin Ratio

An additional attribute indicates the presence or absence of liver disease (binary classification: 1 for disease, 0 for no disease).

3.2 Data preprocessing involved the following steps:

- **Handling Missing Values:** Missing values in the "Albumin and Globulin Ratio" column were imputed using the mean of the non-null values.
- **Categorical Encoding:** The "Gender" column was label encoded (Male = 1, Female = 0).
- **Feature Scaling:** StandardScaler was applied to normalize all numerical features, ensuring uniform input for ML models.
- **Train-Test Split:** The dataset was split into 80% training and 20% testing sets.

3.3 Feature Selection Techniques

To identify the most informative attributes, we employed:

- **Correlation Matrix Analysis:** Features highly correlated with the output class were retained (e.g., Total Bilirubin and Alkaline Phosphotase showed strong correlation).
- **Recursive Feature Elimination (RFE):** Implemented with logistic regression as the base estimator, RFE selected the top six features that contributed most to classification accuracy.
- **Mutual Information (MI):** MI scores were used to quantify the dependency between each feature and the class label, further validating selected attributes.

Final selected features included:

- Age
- Total Bilirubin
- Direct Bilirubin
- Alkaline Phosphotase
- Albumin
- Albumin and Globulin Ratio

3.4 Machine Learning Algorithms Used

To develop a robust prediction model, the following ML algorithms were employed and compared:

- **Support Vector Machine (SVM):** A linear kernel was used, and hyperparameters were tuned using grid search (C = 1.0, kernel = 'linear').
- **Random Forest (RF):** Configured with 100 estimators, max depth = 8, and Gini impurity criterion. This ensemble method handled non-linear patterns effectively.
- **Artificial Neural Network (ANN):** A multi-layer perceptron with one hidden layer (10 neurons), ReLU activation, and Adam optimizer. Trained over 200 epochs with a learning rate of 0.001.

3.5 Model Training and Validation

The models were trained on the preprocessed training set and validated using the test set. K-Fold Cross Validation with k=5 was also implemented to ensure robustness and minimize over fitting.

Fig Performance Metrics



Fig Performance Metrics

The ANN model demonstrated the highest performance, particularly in recall and ROC-AUC, making it suitable for early-stage liver disease detection where sensitivity is crucial.

4 System Architecture

4.1 4.1 Overview of Proposed System

The proposed system integrates a layered architecture to facilitate accurate liver disease prediction using machine learning. The design follows a modular pattern, divided into three primary layers as described in Table 1.

Table 1. System Architecture Layers and Their Functions

Layer	Function
Data Processing Layer	Handles data input validation, cleaning, normalization, and transformation.
Prediction Layer	Hosts trained machine learning models (SVM, RF, ANN) for prediction tasks.
Presentation Layer	Provides a user-friendly interface for input and result visualization.

The system is developed using Python (Flask) for the backend, with the frontend built on HTML/CSS and Bootstrap. Backend models are containerized for modular deployment using Docker.

4.2 Workflow and Data Pipeline

The proposed system follows a structured pipeline, as described in Table 2, which ensures reliable and scalable processing from data entry to result generation.

Table 2. Data Workflow Pipeline

Step	Description
User Input Module	Captures clinical parameters from users via a form-based interface.
Preprocessing Unit	Applies feature scaling (StandardScaler), encodes labels, and handles nulls.
Prediction Engine	Inputs are passed to selected ML model for prediction.
Result Display Module	Outputs prediction as probability and diagnostic status.
Feedback and Logging	Optionally logs predictions to improve model performance in future iterations.

Table System Performance Summary

Metric	Value
Average Prediction Time	< 0.5 seconds
Total Response Time	< 2 seconds
Prediction Accuracy (ANN)	91.3%

This workflow enables timely analysis and interpretation, which is critical in clinical settings.

4.3 User Interface Design

The system's front end has been designed for maximum accessibility, catering to both medical professionals and general users. Key features are summarized in Table 4.

Table 3: User Interface Design Features

Feature	Description
Form-Based Input	Accepts user data such as age, bilirubin, enzymes, and protein levels.
Real-Time Visualization	Displays risk percentage and classification status (e.g., "High Risk").
Model Selection Option	Allows advanced users to switch between ANN, SVM, and Random Forest models.
Export Functionality	Users can download reports in PDF format.

Table4 : User Testing Feedback

User Group	No. of Users	Satisfaction Score (/5)	Avg. Completion Time (s)
Healthcare Professionals	10	4.8	14
General Users	10	4.6	11

This UI design enhances user engagement and ensures practical applicability in clinical scenarios.

5 Experimental Results and Discussion

5.1 Performance Metrics (Accuracy, Precision, Recall, F1-Score)

The performance of the machine learning models was evaluated using standard classification metrics: Accuracy, Precision, Recall, and F1-score. The dataset used for model evaluation was the Indian Liver Patient Dataset (ILPD), consisting of 583 instances and 10 key clinical features. An 80:20 train-test split was used, and cross-validation (5-fold) was applied to ensure generalizability.

Table 4: Model Performance Metrics

Model	Accuracy (%)	Precision	Recall	F1-Score
Support Vector Machine (SVM)	85.7	0.84	0.86	0.85
Random Forest (RF)	89.2	0.88	0.89	0.88
Artificial Neural Network (ANN)	**91.3**	**0.91**	**0.92**	**0.91**

Among the tested models, the ANN outperformed both SVM and Random Forest in all four metrics. Its ability to capture complex, non-linear patterns likely contributed to its superior performance.

5.2 Comparison of Models

A comparative analysis of the models highlights the trade-offs between interpretability, complexity, and performance:

Table 5: Model Comparison Overview

Criterion	SVM	Random Forest	ANN
Training Time	Medium	Low	High
Accuracy	85.7%	89.2%	**91.3%**
Interpretability	High	Moderate	Low
Scalability	Moderate	High	High
Best Use Case	Simpler datasets	Balanced trade-offs	Complex decision tasks

Although Random Forest achieved near-optimal performance with faster training times, the ANN model's accuracy and recall make it more suitable for high-risk prediction tasks such as liver disease screening.

5.3 Interpretation of Results

The high recall value (0.92) of the ANN model indicates that it correctly identifies a high proportion of actual liver disease cases, which is critical for medical applications where false negatives must be minimized. Conversely, precision (0.91) ensures that false positives are also controlled, reducing unnecessary clinical interventions.The ROC-AUC score for ANN was 0.94, further validating its strong discriminatory power between the liver disease and non-disease classes.
A confusion matrix analysis for the ANN model showed:

Table 6: Confusion Matrix – ANN Model

	Predicted: Disease	Predicted: No Disease
Actual: Disease	92	8
Actual: No Disease	7	69

This demonstrates the model's high true positive rate and low false negative rate, which are key for clinical decision-making.

5.4 Implications for Clinical Use

The results demonstrate that machine learning, especially neural networks, can play a transformative role in clinical decision support systems (CDSS). The proposed system:

- Provides **rapid, data-driven diagnostics**, enabling physicians to prioritize at-risk patients.
- Enhances **early detection**, which is vital for liver disease where early intervention can significantly improve patient outcomes.
- Offers a **low-cost, scalable solution** suitable for deployment in both urban and rural healthcare centers.

Moreover, the modular and interpretable structure of the backend allows for integration with Electronic Health Record (EHR) systems, supporting continuous learning and model updates as more patient data becomes available.

6 Conclusion and Future Scope

In conclusion, this research demonstrates the significant potential of integrating machine learning techniques for the early prediction of liver disease. By leveraging clinical datasets and applying robust preprocessing, feature selection, and model training strategies, the study developed a highly accurate predictive system. Among the evaluated algorithms, the Artificial Neural Network (ANN) model achieved the highest performance, with an accuracy of 91.3%, precision and recall of over 90%, and a strong F1-score. These results highlight the suitability of advanced machine learning models in capturing complex patterns within clinical data, leading to effective disease prediction. Furthermore, the developed system incorporates a user-friendly interface and automated prediction pipeline, making it practical for real-world clinical implementation. Such an approach can support healthcare providers in making timely and informed decisions, ultimately improving patient outcomes and reducing the burden of liver disease.Looking ahead, the future scope of this research includes expanding the system to handle larger and more diverse datasets, potentially collected from multiple healthcare institutions across different regions. Incorporating additional features such as lifestyle factors, genetic data, and longitudinal health records can further enhance model robustness and generalizability. Moreover, future studies can explore the integration of explainable AI (XAI) techniques to increase transparency and clinician trust in machine learning predictions. Another promising direction involves the deployment of this system on mobile or cloud-based platforms, enabling remote diagnosis and telehealth applications, especially in low-resource or rural areas. Overall, this work lays the foundation for a scalable, intelligent diagnostic tool that can evolve with emerging data and technologies, playing a vital role in the advancement of predictive healthcare systems.

7 References

1. Asrani, S. K., Devarbhavi, H., Eaton, J., and Kamath, P. S. "Burden of Liver Diseases in the World." *Journal of Hepatology*, vol. 70, no. 1, 2019, pp. 151-171.
2. Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., and Wymer, M. "Global Epidemiology of Nonalcoholic Fatty Liver Disease—Meta-Analytic Assessment of Prevalence, Incidence, and Outcomes." *Hepatology*, vol. 64, no. 1, 2016, pp. 73-84.
3. Castera, L., Friedrich-Rust, M., and Loomba, R. "Noninvasive Assessment of Liver Disease in Patients with Nonalcoholic Fatty Liver Disease." *Gastroenterology*, vol. 156, no. 5, 2019, pp. 1264-1281.
4. Tapper, E. B., and Lok, A. S. "Use of Liver Imaging and Biopsy in Clinical Practice." *New England Journal of Medicine*, vol. 377, no. 8, 2017, pp. 756-768.
5. Esteva, A., Robicquet, A., Ramsundar, B., Kuleshov, V., DePristo, M., Chou, K., et al. "A Guide to Deep Learning in Healthcare." *Nature Medicine*, vol. 25, no. 1, 2019, pp. 24-29.
6. Miotto, R., Wang, F., Wang, S., Jiang, X., and Dudley, J. T. "Deep Learning for Healthcare: Review, Opportunities and Challenges." *Briefings in Bioinformatics*, vol. 19, no. 6, 2018, pp. 1236-1246.
7. Choi, R. Y., Coyner, A. S., Kalpathy-Cramer, J., Chiang, M. F., and Campbell, J. P. "Introduction to Machine Learning, Neural Networks, and Deep Learning." *Translational Vision Science & Technology*, vol. 9, no. 2, 2020, pp. 14-14.
8. Friedrich-Rust, M., et al. "Performance of Acoustic Radiation Force Impulse Imaging for the Staging of Liver Fibrosis: A Pooled Meta-analysis." *Journal of Viral Hepatitis*, vol. 19, no. 2, 2012, pp. e212–e219.
9. Ferraioli, G., et al. "Shear Wave Elastography for Evaluation of Liver Fibrosis." *Journal of Ultrasound in Medicine*, vol. 33, no. 2, 2014, pp. 197–203.
10. Siemens Healthcare. "Enhanced Liver Fibrosis (ELF) Test." *Wired*, 2025, https://www.wired.com/story/siemens-liver-test. Accessed 22 Apr. 2025.
11. Miotto, R., et al. "Deep Learning for Healthcare: Review, Opportunities and Challenges." *Briefings in Bioinformatics*, vol. 19, no. 6, 2018, pp. 1236–1246.
12. Asrani, S. K., et al. "Burden of Liver Diseases in the World." *Journal of Hepatology*, vol. 70, no. 1, 2019, pp. 151–171.
13. Esteva, A., et al. "A Guide to Deep Learning in Healthcare." *Nature Medicine*, vol. 25, no. 1, 2019, pp. 24–29.
14. Wurstle, M. A. T., et al. "Machine Learning Models for Predicting Infected Ascites in Patients with Decompensated Liver Disease." *Hepatology Communications*, vol. 5, no. 3, 2021, pp. 456–465.
15. Zhang, J., et al. "Predicting Mortality Risk in Cirrhotic Patients with Hepatic Encephalopathy Using Machine Learning." *Journal of Hepatology*, vol. 73, no. 5, 2020, pp. 1133–1142.
16. European Medicines Agency. "EU Health Regulator Clears Use of AI Tool in Fatty Liver Disease Trials." *Reuters*, 20 Mar. 2025, https://www.reuters.com/business/healthcare-pharmaceuticals/eu-health-regulator-clears-use-ai-tool-fatty-liver-disease-trials-2025-03-20/. Accessed 22 Apr. 2025.